GlassScriptPhysician profile
Ashley N Bedi
NPI 1770076994
$982.02
in general payments reported to CMS, 2019-2025
18 companies · $982 in 2025
The $982 reported for 2025 was more than what 87% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $160.14 | 2025 | Nayzilam, Zilbrysq, Fintepla |
| Merz Pharmaceuticals, LLC | $147.34 | 2025 | Inbrija, Xeomin |
| Abbvie INC. | $140.74 | 2025 | |
| Livanova USA, INC. | $68.42 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Biotech, INC. | $60.01 | 2025 | |
| Argenx US, INC. | $57.01 | 2025 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $51.13 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $42.62 | 2025 | Rytary, Crexont, Ongentys |
| Eisai INC. | $40.93 | 2025 | |
| Biogen, INC. | $40.71 | 2025 | Leqembi, Tysabri, Vumerity |
| Tanabe Pharma America, INC. | $30.26 | 2025 | Radicava |
| Lundbeck LLC | $27.40 | 2025 | Rexulti |
| Ani Pharmaceuticals, INC. | $25.82 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $22.17 | 2025 | Kisunla |
| Azurity Pharmaceuticals, INC. | $21.49 | 2025 | Zonisade |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.46 | 2025 | Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $14.33 | 2025 | Ultomiris |
| Microtransponder, INC. | $14.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Bedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.